THERAPY DOSSIER · th-f4f1038bccf5

JM4, a 19 amino acid non-haematopoietic erythropoietin derived peptide covering residues 28 to 46

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03887065 ↗EARLY_PHASE1unknown

Magnetic Resonance Imaging 12 Day Study for Multiple Sclerosis/Clinically Isolated Syndrome Trial of JM-4 Novel Human Peptide

Multiple Sclerosis

Enrolment: 15 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26715414 ↗2016Reported benefit

Beneficial Effect of Erythropoietin Short Peptide on Acute Traumatic Brain Injury.

MouseTBIControlled cortical impactC57BL/6MaleTreatment window remained open for at least 9 h after injury

Model: Controlled cortical impact traumatic brain injury

JM4 reduced neural cell death and lesion size at 3 and 8 days after controlled cortical impact and improved functional recovery, with efficacy retained when given up to 9 h after injury.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…